Although our preliminary experiments employing three BC cell lines suggest that moderate knock-down of AML1 expression is not sufficient to render the cells more sensitive to imatinib (Figure S13), the overall findings may imply that elevated expression of wt.AML1 could in part lead to imatinib-resistance, and culminates in disease progression to BC. Here, RUNX1 is linked to breast cancer.